What's Happening?
Darling Ingredients Inc. announced its third-quarter 2026 financial results, reporting earnings of $1.67 per share, which fell short of analysts' expectations of $1.83. Despite this, the company's revenue matched forecasts at $1.79 billion. Net income
saw a significant increase to $267 million, up from $19 million in the previous year, driven by stronger operations and improved cash generation. The combined adjusted EBITDA for the quarter more than doubled to approximately $514 million. Darling Ingredients also reduced its net debt by about $420 million, bringing its leverage down to 1.7 times. The company reaffirmed its full-year 2026 adjusted EBITDA guidance, projecting between $2.2 billion and $2.3 billion. However, the Food Ingredients segment, which includes gelatin and collagen, experienced a slight dip in gross margin from 27.5% to 26.5% of net sales, attributed to tariff-driven inventory drawdowns, particularly from Brazil. Chief Financial Officer Robert Day noted that while sales growth did not translate into equally strong profit growth in this segment, demand for water-soluble collagen continues to grow at near double-digit rates.
Why It's Important?
The mixed financial results from Darling Ingredients highlight the complex interplay of global trade policies and market demand on U.S. companies. The impact of Brazilian tariffs on collagen and gelatin supply chains is a significant factor, as the U.S. relies on imports for raw materials like beef hides. This situation forces U.S. buyers to either absorb increased costs or seek alternative sourcing, potentially shifting trade flows to countries like China and Paraguay, where Darling Ingredients is expanding its capacity. The company's strategic focus on higher-margin products like collagen peptides and biomedical grades, which can earn 2.5 to 11 times more than commodity gelatin, indicates a broader industry trend towards value-added products. This shift is crucial for maintaining profitability amidst volatile raw material costs and trade barriers, affecting both producers and consumers of these ingredients in various sectors, including food, pharmaceuticals, and nutraceuticals.
What's Next?
Darling Ingredients is targeting the closing of its joint venture with Tessenderlo Group in the first quarter of 2027, pending regulatory approvals. This venture aims to combine Darling's Rousselot collagen and gelatin business with PB Leiner, potentially reshaping the global gelatin market. The company also plans to continue its expansion of production sites outside Brazil, with new capacity in Kaiping, China, and Paraguay, to mitigate the impact of tariffs and secure raw material access. The future trajectory of Brazilian tariffs, particularly the combined 37.5% burden, will be a critical factor. If these tariffs persist without being absorbed into shelf prices, more U.S.-bound volume is likely to shift to other origins. Conversely, if exemptions widen or costs are absorbed, demand could resume, and Brazilian capacity might regain its U.S. volumes. The industry will also closely watch the continued shift towards high-purity and application-specific gelatin and collagen products, which are expected to drive future growth and profitability.
Beyond the Headlines
The challenges faced by Darling Ingredients underscore a broader trend in global supply chains where geopolitical factors and trade policies increasingly dictate market dynamics. The move towards higher-margin, specialized products like biomedical-grade gelatin and collagen peptides reflects an industry-wide effort to de-commoditize and create more resilient business models. This strategic pivot not only enhances profitability but also addresses evolving consumer demands for health and wellness products. The emphasis on securing diverse raw material sources and expanding production geographically highlights the vulnerability of single-source supply chains and the need for companies to build flexibility and redundancy. Furthermore, the regulatory review of the joint venture with Tessenderlo Group signals ongoing consolidation within the gelatin and collagen market, which could lead to fewer, larger players dominating the industry and potentially influencing pricing and innovation.
